ChiCTR2100049252 版本V1.0 版本创建时间2022/03/01 20:03:32 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100049252 

最近更新日期:

Date of Last Refreshed on:

2021-07-28 08:32:30 

注册时间:

Date of Registration:

2021-07-28 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

请于伦理委员会批准后才开始征募参试者,并与我们联系上传伦理批件。 内窥镜手术系统的探索性研究

Public title:

A Feasibility Study to Accomplish Robotic-Assisted Surgery.

注册题目简写:

English Acronym:

研究课题的正式科学名称:

图迈?内窥镜手术系统用于盆腔机器人辅助手术的探索性研究

Scientific title:

A Feasibility Study to Accomplish Robotic-Assisted Surgery Using Toumai Endoscopic Surgery System in Pelvic Surgery.

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张敏 

研究负责人:

华克勤 

Applicant:

Zhang Min 

Study leader:

Keqin, Hua 

申请注册联系人电话:

Applicant telephone:

13816382672

研究负责人电话:

Study leader's telephone:

15921515900

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

zhangmin@microport.com

研究负责人电子邮件:

Study leader's E-mail:

huakeqinjiaoshou@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海浦东新区张东路1601号

研究负责人通讯地址:

上海沈阳路128号

Applicant address:

1601 Rd, Pudong District, Shanghai

Study leader's address:

128 Shenyang Rd,Shanghai

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海微创医疗机器人(集团)股份有限公司

Applicant's institution:

Shanghai Microport Medbot(Group)Co.,Ltd

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

否/No

Approved by ethic committee:

No

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

复旦大学附属妇产科医院

Primary sponsor:

Obstetrics & Gynecology Hospital of Fudan University

研究实施负责(组长)单位地址:

上海沈阳路128号

Primary sponsor's address:

128 Shenyang Rd,Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

复旦大学附属妇产科医院

具体地址:

沈阳路128号

Institution
hospital:

Obstetrics & Gynecology Hospital of Fudan University

Address:

128 Shenyang Road

经费或物资来源:

自筹

Source(s) of funding:

Self-financing

Target disease:

requiring laparoscopic surgery in pelvic surgery

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

单臂 

Study design:

Single arm 

研究目的:

探索内窥镜手术系统应用于盆腔手术的安全性和有效性。  

Objectives of Study:

Explore the safety and effectiveness to accomplish robotic-assisted surgery using Toumai Endoscopic Surgery System in Pelvic Surgery.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)18周岁≤年龄≤80周岁;
(2)需接受盆腔内窥镜手术治疗,并有以下手术治疗指征之一:
?子宫切除手术、子宫附件切除手术
(3)受试者或其代理人自愿参加并签署知情同意书,愿意接受相关检查和临床随访

Inclusion criteria

(1)Aged between 18 to 80 years.
(2)Patient with at least one of the following surgical indications: hysterectomy or adnexal hysterectomy.
(3)All subjects are required to give informed consent to the this study and sign informed consent voluntarily. Willing to cooperate and complete all follow-up visits

排除标准:

(1)妊娠或哺乳期女性。
(2)恶性肿瘤临床分期为IV期者。
(3)需行急诊手术者。
(4)存在活动性出血、凝血功能严重异常(凝血酶原时间(PT)或国际标准化比值(INR)高于正常值上限1.5 倍);
(5)有严重心血管或循环系统疾病且不能耐受手术。
(6)近1个月内参与过其他临床研究。
(7)无法理解研究要求,或不能完成研究随访计划。
(8)研究者认为有其他不适合入组的情况。

Exclusion criteria:

(1)Pregnant or lactating women
(2)The clinical stage of malignant tumor is IV
(3)Requiring emergency operation
(4)Active bleeding and severe abnormal coagulation
(5)Severe cardiovascular or circulatory diseases.
(6)Paticipated other clinical trials in the last 1 months.
(7)Unable to understand research's requirements or unable to complete all the follow-up visits.
(8)Other conditions judged by the investigators.

研究实施时间:

Study execute time:

From 2021-09-01 00:00:00 To 2021-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-10-01 00:00:00 To 2022-01-31 00:00:00  

干预措施:

Interventions:

组别:

试验组

样本量:

20

Group:

Experimental group

Sample size:

干预措施:

机器人辅助手术

干预措施代码:

Intervention:

Robotic-assisted surgery

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China 

Province:

Shanghai 

City:

 

单位(医院):

复旦大学附属妇产科医院 

单位级别:

三甲 

Institution
hospital:

Obstetrics & Gynecology Hospital of Fudan University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

手术成功率

指标类型:

主要指标

Outcome:

Success rate of surgery

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

非随机

Randomization Procedure (please state who generates the random number sequence and by what method):

Non-randomized

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

Excel

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Excel

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2021-07-28 08:32:30